Search 33,000+ CME courses
Back

PRIME Education, Inc. (PRIME®)

  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Immunoconjugates
  • Triple Negative Breast Neoplasms

Unlocking Expertise in Bispecific ADCs: Therapeutic Rationale and Emerging Data in NSCLC, TNBC, and Urothelial Carcinoma

Bispecific antibody-drug conjugates (ADCs) are an emerging class of ADCs poised to expand treatment options for solid tumors. Bispecific ADCs are unique in their dual-targeting mechanisms that set them apart from single target therapies. Understanding their distinction is essential as they move toward clinical practice. With this interactive Booster Quiz, test your knowledge on mechanisms, therapeutic rationale, and emerging clinical trial data surrounding bispecific ADCs in non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and urothelial carcinoma. In this quiz, you will: Receive immediate expert-supported feedback on your answer selections Compare your expertise with peers across disciplines Learn about the latest clinical trial evidence on the efficacy of bispecific ADCs in solid tumors. Through the components of this educational activity, you have the opportunity to earn 1.75 CE credits in total. You can earn 0.5 CE credits by participating in the Booster Quiz. Additionally, if you choose to engage with the SynopsiMedEd Related Evidence articles, you can earn up to 1.25 CE credits. If you decide not to engage in completion of the entirety of these articles, you can still claim partial credit based on your level of participation. Total Possible Credits: 1.75 CE Credits from PRIME Booster Quiz: 0.5 CE Credits from SynopsiMedEd Related Evidence: 1.25 CE

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AAPA Category 1 Credit™Up to 0.5 creditsAMA PRA Category 1 Credit™Up to 0.5 creditsNursingUp to 0.5 creditsPharmacyUp to 0.5 credits

MOC types

ABIM — Medical KnowledgeUp to 0.5 points

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Pricing

Free

Reported to ACCME by the provider

  • Enduring / On-demand
  • Credit · Up to 0.5 credits
  • MOC · Up to 0.5 points
  • Commercial Support
  • Released
    Jul 10, 2026
  • Last day to claim credit
    Jul 10, 2027 9 months left

Related courses

See all

Other providers’ courses on the same topic

More from PRIME Education, Inc. (PRIME®)

See all

This provider’s courses closest to this one